Design of Experiments Gains Ground in Biopharma Development

News
Article
Pharmaceutical TechnologyPharmaceutical Technology-12-15-2019
Volume 2019 eBook
Issue 3
Pages: 14–16

Long a staple for quality by design and solid dosage form manufacturing, design of experiments is becoming an integral part of biopharma upstream process development.

Long a staple for quality by design and solid dosage form manufacturing, design of experiments is becoming an integral part of biopharma upstream process development, as equipment evolves and use of process analytical technology increases.

Design of experiments (DoE) is used by drug developers to gain deeper insights into their products and processes.

By using statistical methods to perform multivariate analysis, the approach allows users to assess the impact of various factors on each other and on an outcome or may make these techniques easier to apply.

Read this article in Pharmaceutical Technology’s December 2019 Regulatory Sourcebook.

Article Details

Pharmaceutical Technology
eBook: Regulatory Sourcebook, December 2019
December 2019
Pages: 14–16

Citation

When referring to this article, please cite it as A. Shanley, “Moving from Compliance to Quality," Pharmaceutical Technology Regulatory Sourcebook eBook (December 2019).

Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Related Content